Free Trial
→ Trump Exec Order 14179 is wealth “gift” to good Americans? (From Paradigm Press) (Ad) Buy CGEM Stock  Free CGEM Stock Alerts

Cullinan Therapeutics (CGEM) Financials

Cullinan Therapeutics logo
$7.81 -0.08 (-1.01%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$7.81 0.00 (0.00%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Cullinan Therapeutics

Annual Income Statements for Cullinan Therapeutics

This table shows Cullinan Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders		 -167 -153 111
Consolidated Net Income / (Loss)		 -168 -155 109
Net Income / (Loss) Continuing Operations		 -168 -155 109
Total Pre-Tax Income 		-167 -169 151
Total Operating Income		 -197 -191 145
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 197 191 -145
Selling, General & Admin Expense		 54 42 40
Research & Development Expense		 143 148 92
Total Other Income / (Expense), net		 29 22 6.67
Interest & Investment Income		 30 22 6.61
Other Income / (Expense), net		 -0.20 0.24 0.06
Income Tax Expense		 0.12 -14 42
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.19 -1.94 -2.02
Basic Earnings per Share		 $0.00 ($35.33) $2.46
Weighted Average Basic Shares Outstanding		 0.00 42.16M 45.16M
Diluted Earnings per Share		 $0.00 ($35.33) $2.38
Weighted Average Diluted Shares Outstanding		 0.00 42.16M 46.64M
Weighted Average Basic & Diluted Shares Outstanding		 58.51M 43.07M 39.33M

Quarterly Income Statements for Cullinan Therapeutics

This table shows Cullinan Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -48 -41 -42 -37 -24 -39 -32 -58 -27 -25
Consolidated Net Income / (Loss)		 -48 -41 -42 -37 -26 -39 -32 -58 -27 -25
Net Income / (Loss) Continuing Operations		 -48 -41 -42 -37 -26 -39 -32 -58 -27 -25
Total Pre-Tax Income 		-48 -41 -42 -37 -40 -39 -32 -58 -29 -27
Total Operating Income		 -55 -49 -50 -43 -45 -45 -38 -63 -33 -30
Total Operating Expenses		 55 49 50 43 45 45 38 63 33 30
Selling, General & Admin Expense		 15 13 14 12 11 11 10 11 11 10
Research & Development Expense		 40 36 36 31 35 34 27 52 21 20
Total Other Income / (Expense), net		 7.52 8.30 8.00 5.65 5.80 6.06 5.39 4.62 3.66 2.35
Interest & Investment Income		 7.51 8.38 8.07 5.69 5.92 5.88 5.32 4.51 3.36 2.35
Other Income / (Expense), net		 0.01 -0.09 -0.07 -0.04 -0.12 0.18 0.07 0.11 0.30 0.00
Basic Earnings per Share		 $2.30 ($0.69) ($0.75) ($0.86) ($32.18) ($0.91) ($0.82) ($1.42) ($0.63) ($0.54)
Weighted Average Basic Shares Outstanding		 0.00 58.34M 55.05M 43.01M 42.16M 42.73M 39.95M 40.68M 45.16M 45.61M
Diluted Earnings per Share		 $2.30 ($0.69) ($0.75) ($0.86) ($32.18) ($0.91) ($0.82) ($1.42) ($0.58) ($0.54)
Weighted Average Diluted Shares Outstanding		 0.00 58.34M 55.05M 43.01M 42.16M 42.73M 39.95M 40.68M 46.64M 45.61M
Weighted Average Basic & Diluted Shares Outstanding		 58.51M 58.23M 57.98M 57.63M 43.07M 42.78M 42.73M 40.68M 39.33M 45.77M

Annual Cash Flow Statements for Cullinan Therapeutics

This table details how cash moves in and out of Cullinan Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents		 -15 -58 96
Net Cash From Operating Activities		 -145 -134 -127
Net Cash From Continuing Operating Activities		 -145 -134 -127
Net Income / (Loss) Continuing Operations		 -168 -155 109
Consolidated Net Income / (Loss)		 -168 -155 109
Depreciation Expense		 0.31 0.31 0.09
Amortization Expense		 -15 -10 1.29
Non-Cash Adjustments To Reconcile Net Income		 38 31 -248
Changes in Operating Assets and Liabilities, net		 -0.39 -0.34 11
Net Cash From Investing Activities		 -136 36 249
Net Cash From Continuing Investing Activities		 -136 36 249
Purchase of Property, Plant & Equipment		 0.00 -0.21 -1.13
Purchase of Investments		 -721 -373 -378
Sale and/or Maturity of Investments		 585 409 353
Net Cash From Financing Activities		 266 41 -26
Net Cash From Continuing Financing Activities		 266 41 -26
Repayment of Debt		 0.00 0.00 -2.20
Payment of Dividends		 -4.45 0.00 -33
Issuance of Preferred Equity		 0.00 1.83 2.38
Issuance of Common Equity		 271 39 6.02
Other Financing Activities, net		 0.00 0.00 1.15
Cash Income Taxes Paid		 -2.27 -4.43 38

Quarterly Cash Flow Statements for Cullinan Therapeutics

This table details how cash moves in and out of Cullinan Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -19 -13 41 -24 34 -77 20 -34 -87 -111
Net Cash From Operating Activities		 -37 -34 -36 -38 -18 -34 -31 -51 -25 -54
Net Cash From Continuing Operating Activities		 -37 -34 -36 -38 -18 -34 -31 -51 -25 -54
Net Income / (Loss) Continuing Operations		 -48 -41 -42 -37 -26 -39 -32 -58 -27 -25
Consolidated Net Income / (Loss)		 -48 -41 -42 -37 -26 -39 -32 -58 -27 -25
Depreciation Expense		 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.07 0.06 0.01
Amortization Expense		 -3.51 - - -3.31 -3.62 - - -1.37 -0.60 0.16
Non-Cash Adjustments To Reconcile Net Income		 9.63 16 3.50 8.23 7.65 12 4.40 7.26 7.69 5.26
Changes in Operating Assets and Liabilities, net		 4.82 1.84 -1.15 -5.90 3.31 -0.18 -4.65 1.18 -5.01 -35
Net Cash From Investing Activities		 16 20 -185 13 51 -43 12 15 -29 -58
Net Cash From Continuing Investing Activities		 16 20 -185 13 51 -43 12 15 -29 -58
Purchase of Investments		 -168 -97 -325 -131 -66 -137 -81 -89 -160 -124
Sale and/or Maturity of Investments		 184 117 140 144 117 94 94 104 133 61
Net Cash From Financing Activities		 1.58 1.33 262 1.09 0.25 0.11 39 1.79 -33 1.43
Net Cash From Continuing Financing Activities		 1.58 1.33 262 1.09 0.25 0.11 39 1.79 -33 1.43
Issuance of Common Equity		 264 1.98 3.34 1.09 39 0.11 0.21 -0.04 0.19 1.43
Other Financing Activities, net		 -263 - - - -38 - - - - -

Annual Balance Sheets for Cullinan Therapeutics

This table presents Cullinan Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets		 622 484 561
Total Current Assets		 415 480 474
Cash & Equivalents		 83 98 156
Short-Term Investments		 316 369 311
Prepaid Expenses		 16 13 7.18
Plant, Property, & Equipment, net		 0.68 0.99 1.17
Total Noncurrent Assets		 206 3.00 85
Long-Term Investments		 204 0.00 81
Other Noncurrent Operating Assets		 2.03 3.00 4.59
Total Liabilities & Shareholders' Equity		 622 484 561
Total Liabilities		 31 30 26
Total Current Liabilities		 31 28 22
Accounts Payable		 1.68 2.49 2.66
Accrued Expenses		 28 24 14
Other Current Liabilities		 1.30 1.44 1.42
Total Noncurrent Liabilities		 0.85 2.15 3.59
Other Noncurrent Operating Liabilities		 0.85 2.15 3.59
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 590 454 535
Total Preferred & Common Equity		 590 454 535
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 590 454 535
Common Stock		 959 655 585
Retained Earnings		 -368 -201 -48
Accumulated Other Comprehensive Income / (Loss)		 -0.13 -0.13 -2.60
Noncontrolling Interest		 0.00 0.19 0.00

Quarterly Balance Sheets for Cullinan Therapeutics

This table presents Cullinan Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 653 681 449 495 522 515 617
Total Current Assets		 592 678 446 477 498 399 582
Cash & Equivalents		 102 115 74 65 142 122 243
Short-Term Investments		 476 547 359 402 350 269 333
Prepaid Expenses		 14 15 13 10 6.44 8.33 6.12
Plant, Property, & Equipment, net		 0.76 0.84 0.91 1.07 1.16 1.24 0.79
Total Noncurrent Assets		 60 2.58 2.80 17 23 115 34
Long-Term Investments		 58 0.00 0.00 14 19 110 29
Other Noncurrent Operating Assets		 2.48 2.58 2.80 3.38 3.96 4.28 4.96
Total Liabilities & Shareholders' Equity		 653 681 449 495 522 515 617
Total Liabilities		 25 25 24 26 22 29 31
Total Current Liabilities		 24 23 22 23 20 26 27
Accounts Payable		 2.12 1.56 3.71 0.95 2.49 2.03 1.52
Accrued Expenses		 21 21 17 21 16 18 14
Other Current Liabilities		 1.26 1.22 1.33 1.55 1.65 1.55 0.70
Total Noncurrent Liabilities		 1.19 1.52 1.84 2.45 2.73 3.17 3.99
Noncurrent Deferred Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 1.19 1.52 1.84 2.45 2.73 3.17 3.99
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 628 656 426 469 500 486 586
Total Preferred & Common Equity		 628 656 426 469 500 486 586
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 - -
Total Common Equity		 628 656 426 469 500 486 586
Common Stock		 947 937 664 647 639 593 611
Retained Earnings		 -321 -280 -238 -177 -138 -106 -21
Accumulated Other Comprehensive Income / (Loss)		 0.97 -0.48 -0.33 -1.05 -1.63 -1.24 -3.93
Noncontrolling Interest		 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Annual Metrics And Ratios for Cullinan Therapeutics

This table displays calculated financial ratios and metrics derived from Cullinan Therapeutics' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% -100.00%
EBITDA Growth		 -5.77% -237.38% 315.13%
EBIT Growth		 -3.28% -231.89% 312.92%
NOPAT Growth		 -3.05% -228.15% 319.44%
Net Income Growth		 -8.04% -242.04% 261.81%
EPS Growth		 100.00% -1,584.45% 0.00%
Operating Cash Flow Growth		 -8.21% -6.01% -191.63%
Free Cash Flow Firm Growth		 -3.13% -219.36% 315.58%
Invested Capital Growth		 0.63% -0.21% -139.48%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -4.60% -8.84% 2.36%
EBIT Q/Q Growth		 -5.03% -7.49% 1.42%
NOPAT Q/Q Growth		 -5.10% -7.23% -26.96%
Net Income Q/Q Growth		 -15.18% 0.97% 6.97%
EPS Q/Q Growth		 100.00% -847.19% 0.00%
Operating Cash Flow Q/Q Growth		 -14.59% 4.86% -8.40%
Free Cash Flow Firm Q/Q Growth		 -2.84% -0.68% -30.94%
Invested Capital Q/Q Growth		 -59.78% -18.05% 31.67%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.07% 91.65% 72.16%
Interest Burden Percent		 84.95% 88.67% 104.57%
Effective Tax Rate		 0.00% 0.00% 27.84%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -32.10% -31.37% 22.74%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -32.09% -31.36% 22.73%
Return on Equity Simple (ROE_SIMPLE)		 -28.39% -34.19% 20.41%
Net Operating Profit after Tax (NOPAT)		 -138 -134 104
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.55% -4.20% 0.98%
Return On Investment Capital (ROIC_SIMPLE)		 -23.35% -29.47% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -197 -191 145
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -212 -201 146
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.20 0.96 0.90
Price to Tangible Book Value (P/TBV)		 1.20 0.96 0.90
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 4.34
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 23.03%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.03 -1.02
Leverage Ratio		 1.06 1.06 1.04
Compound Leverage Factor		 0.90 0.94 1.09
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.04% 0.00%
Common Equity to Total Capital		 100.00% 99.96% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 12.38 7.87 12.80
Noncontrolling Interest Sharing Ratio		 0.02% 0.02% 0.04%
Liquidity Ratios		 - - -
Current Ratio		 13.53 17.07 21.09
Quick Ratio		 13.02 16.60 20.77
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -138 -134 112
Operating Cash Flow to CapEx		 0.00% -64,555.29% -12,155.85%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -13 -13 -13
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.08 -0.03 -7.66
Enterprise Value (EV)		 106 -31 -65
Market Capitalization		 709 436 483
Book Value per Share		 $10.14 $10.61 $11.69
Tangible Book Value per Share		 $10.14 $10.61 $11.69
Total Capital		 590 454 535
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -603 -467 -548
Capital Expenditures (CapEx)		 0.00 0.21 1.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -15 -15
Debt-free Net Working Capital (DFNWC)		 384 452 452
Net Working Capital (NWC)		 384 452 452
Net Nonoperating Expense (NNE)		 30 21 -4.81
Net Nonoperating Obligations (NNO)		 -603 -467 -548
Total Depreciation and Amortization (D&A)		 -15 -9.84 1.39
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($3.69) $2.46
Adjusted Weighted Average Basic Shares Outstanding		 0.00 41.55M 45.16M
Adjusted Diluted Earnings per Share		 $0.00 ($3.69) $2.38
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 41.55M 46.64M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 58.51M 43.07M 39.33M
Normalized Net Operating Profit after Tax (NOPAT)		 -138 -134 -95
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 -2.65% 0.00% 30.48%
Augmented Payout Ratio		 -2.65% 0.00% 30.48%

Quarterly Metrics And Ratios for Cullinan Therapeutics

This table displays calculated financial ratios and metrics derived from Cullinan Therapeutics' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -18.98% -8.64% -33.55% 27.66% -49.60% -51.97% -115.59% -101.74% 4.31% -69.74%
EBIT Growth		 -20.70% -8.61% -33.47% 31.31% -41.14% -51.39% -115.68% -91.84% 5.92% -61.97%
NOPAT Growth		 -21.02% -7.98% -33.03% 31.50% -39.49% -52.00% -115.15% -92.17% 5.06% -61.99%
Net Income Growth		 -86.39% -3.51% -30.47% 35.78% 5.63% -57.42% -118.51% -350.99% 20.81% -36.32%
EPS Growth		 107.15% 24.18% 8.54% 39.44% -5,448.28% -68.52% -121.75% -425.93% 0.00% -35.00%
Operating Cash Flow Growth		 -102.01% 0.01% -17.05% 25.00% 27.43% 37.19% -21.97% -132.78% -64.68% -415.15%
Free Cash Flow Firm Growth		 -21.39% 6.50% 39.10% -112.46% -109.71% -2,551.35% -128.84% 50.80% 46.67% 88.43%
Invested Capital Growth		 0.63% 26.58% 42.20% 52.59% -0.21% 42.00% 78.10% -248.43% -139.48% -19,337.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -19.66% 2.31% -8.13% 5.87% -9.25% -20.10% 41.43% -94.66% -10.98% -112.32%
EBIT Q/Q Growth		 -12.46% 2.31% -16.42% 5.63% -1.20% -20.05% 40.09% -93.90% -8.55% -112.43%
NOPAT Q/Q Growth		 -12.68% 2.34% -16.37% 5.49% -0.53% -20.31% 40.08% -92.46% -9.55% -111.99%
Net Income Q/Q Growth		 -17.47% 3.49% -12.55% -46.07% 34.76% -21.63% 44.59% -114.64% -8.83% -114.30%
EPS Q/Q Growth		 433.33% 8.00% 12.79% -59.26% -3,436.26% -10.98% 42.25% -144.83% -7.41% -114.32%
Operating Cash Flow Q/Q Growth		 -7.28% 5.93% 5.11% -110.95% 46.89% -10.11% 39.20% -104.13% 54.04% -113.82%
Free Cash Flow Firm Q/Q Growth		 -3.91% 6.15% -3.56% -20.20% 19.97% 38.87% -261.30% -18.65% -911.85% -100.66%
Invested Capital Q/Q Growth		 -59.78% -30.57% 14.59% 44.23% -18.05% -2.79% 29.94% -17.86% 31.67% 61.18%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.25% 100.00% 100.00% 100.00% 64.41% 100.00% 100.00% 100.00% 93.58% 90.80%
Interest Burden Percent		 86.35% 82.87% 83.89% 86.77% 87.02% 86.95% 85.82% 92.80% 89.59% 92.10%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -32.10% -26.53% -24.94% -29.47% -31.37% -29.69% -25.78% 14.13% 22.74% 19.79%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -32.09% -26.53% -24.94% -29.47% -31.36% -29.69% -25.78% 14.12% 22.73% 19.75%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -23.17% -21.96% -31.55% 0.00% -33.41% -28.49% 13.17% 0.00% 17.42%
Net Operating Profit after Tax (NOPAT)		 -39 -34 -35 -30 -32 -32 -26 -44 -23 -21
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.70% -1.14% -1.20% -1.55% 1.24% -1.38% -1.01% -3.12% -0.87% -0.77%
Return On Investment Capital (ROIC_SIMPLE)		 -6.53% - - - -7.01% - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -55 -49 -50 -43 -46 -45 -38 -63 -32 -30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -58 -49 -50 -46 -49 -45 -37 -64 -33 -30
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.20 1.55 1.53 1.72 0.96 0.82 0.85 0.83 0.90 1.00
Price to Tangible Book Value (P/TBV)		 1.20 1.55 1.53 1.72 0.96 0.82 0.85 0.83 0.90 1.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.16 4.34 5.54
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.24% 23.03% 18.04%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.02 -1.01 -1.03 -1.03 -1.03 -1.05 -1.01 -1.02 -1.02
Leverage Ratio		 1.06 1.05 1.04 1.06 1.06 1.05 1.08 1.05 1.04 1.04
Compound Leverage Factor		 0.91 0.87 0.87 0.92 0.92 0.92 0.92 0.98 0.93 0.96
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.04% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 99.96% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 13.13 23.04 24.46 18.60 8.86 9.26 11.83 8.41 11.76 12.15
Noncontrolling Interest Sharing Ratio		 0.02% 0.00% 0.00% 0.00% 0.02% 0.00% 0.01% 0.08% 0.04% 0.20%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 13.53 24.46 28.87 20.33 17.07 20.33 25.32 15.25 21.09 21.47
Quick Ratio		 13.02 23.88 28.22 19.75 16.60 19.90 24.99 14.93 20.77 21.24
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -39 -37 -40 -38 -32 -40 -65 -18 -15 -1.50
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -63,277.55% -32,073.58% -2,832.54% -21,654.58%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -13 -8.19 -6.27 -7.35 -13 -11 -11 -15 -13 -19
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.08 2.97 4.58 8.15 -0.03 8.08 39 -26 -7.66 -19
Enterprise Value (EV)		 106 334 343 301 -31 -93 -87 -99 -65 -21
Market Capitalization		 709 971 1,005 734 436 387 424 402 483 585
Book Value per Share		 $10.14 $10.83 $11.39 $9.88 $10.61 $10.97 $12.69 $12.35 $11.69 $12.85
Tangible Book Value per Share		 $10.14 $10.83 $11.39 $9.88 $10.61 $10.97 $12.69 $12.35 $11.69 $12.85
Total Capital		 590 628 656 426 454 469 500 486 535 586
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -603 -636 -662 -433 -467 -480 -510 -501 -548 -605
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.16 0.88 0.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -10 -8.17 -9.22 -15 -13 -13 -18 -15 -21
Debt-free Net Working Capital (DFNWC)		 384 568 654 424 452 453 479 373 452 555
Net Working Capital (NWC)		 384 568 654 424 452 453 479 373 452 555
Net Nonoperating Expense (NNE)		 9.11 6.36 7.01 7.25 -6.28 7.51 5.89 14 4.26 4.05
Net Nonoperating Obligations (NNO)		 -603 -636 -662 -433 -467 -480 -510 -501 -548 -605
Total Depreciation and Amortization (D&A)		 -3.43 0.08 0.08 -3.23 -3.54 0.08 0.08 -1.30 -0.54 0.17
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $2.30 ($0.69) ($0.75) ($0.86) ($32.18) ($0.91) ($0.82) $0.00 ($0.63) ($0.54)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 58.34M 55.05M 43.01M 42.16M 42.73M 39.95M 40.68M 45.16M 45.61M
Adjusted Diluted Earnings per Share		 $2.30 ($0.69) ($0.75) ($0.86) ($32.18) ($0.91) ($0.82) $0.00 ($0.58) ($0.54)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 58.34M 55.05M 43.01M 42.16M 42.73M 39.95M 40.68M 46.64M 45.61M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 58.51M 58.23M 57.98M 57.63M 43.07M 42.78M 42.73M 40.68M 39.33M 45.77M
Normalized Net Operating Profit after Tax (NOPAT)		 -39 -34 -35 -30 -32 -32 -26 -44 -23 -21
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 -2.65% -3.06% -2.63% 0.00% 0.00% 0.00% 0.00% 0.00% 30.48% 0.00%
Augmented Payout Ratio		 -2.65% -3.06% -2.63% 0.00% 0.00% 0.00% 0.00% 0.00% 30.48% 0.00%

Frequently Asked Questions About Cullinan Therapeutics' Financials

When does Cullinan Therapeutics's financial year end?

According to the most recent income statement we have on file, Cullinan Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Cullinan Therapeutics' net income changed over the last 2 years?

Cullinan Therapeutics' net income appears to be on an upward trend, with a most recent value of -$167.58 million in 2024, falling from $109.20 million in 2022. The previous period was -$155.10 million in 2023. Check out Cullinan Therapeutics' forecast to explore projected trends and price targets.

What is Cullinan Therapeutics's operating income?
Cullinan Therapeutics's total operating income in 2024 was -$196.92 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $196.92 million
How has Cullinan Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Cullinan Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Cullinan Therapeutics have?

Cullinan Therapeutics' total liabilities were at $31.50 million at the end of 2024, a 4.0% increase from 2023, and a 20.7% increase since 2022.

How much cash does Cullinan Therapeutics have?

In the past 2 years, Cullinan Therapeutics' cash and equivalents has ranged from $83.01 million in 2024 to $156.15 million in 2022, and is currently $83.01 million as of their latest financial filing in 2024.

How has Cullinan Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Cullinan Therapeutics' book value per share changed from 11.69 in 2022 to 10.14 in 2024, a change of -13.3%.


Related Companies

This page (NASDAQ:CGEM) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored
$19 for a FULL YEAR of stock picks?!
Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...
Behind the Markets | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
After Monday, price goes up 600% (hurry)
Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...
Timothy Sykes | Sponsored
We’ve Entered the Most Bullish Phase of the Cycle
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...
Crypto Swap Profits | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...
Brownstone Research | Sponsored